

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: **MS Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 14, 2004

Signature: 

Nabeela R. McMullan



Docket No.: 30610/40037
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Zankel *et al.*

Application No.: 10/812,849

Group Art Unit: 1614

Filed: March 30, 2004

Examiner: Not Yet Assigned

For: **MEGALIN-BASED DELIVERY OF
THERAPEUTIC COMPOUNDS TO THE
BRAIN AND OTHER TISSUES**

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO - 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

All patents and publications in the attached Form PTO - 1449 are not supplied because they were previously cited by or submitted to the Office in a prior application no. 10/600,862, filed May 25, 2004, which application is relied upon in this application for an earlier filing date under 35 U.S.C. 120.

The submission of this PTO-1449 and IDS is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for the instant application under any section of 35 U.S.C. §102 or 35 U.S.C. §103.

Application No.: 10/812,849

Docket No.: 30610/40037

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No additional fees are believed to be necessary, however, the Commissioner is hereby authorized to charge any deficiency in the fees filed or credit any overpayments to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: June 14, 2004

Respectfully submitted,

By 

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicants



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket No.
30610/40037Serial No.
10/812,849

INFORMATION DISCLOSURE STATEMENT

Applicant
Zankel *et al.*Filing Date
March 30, 2004Group
1614

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,018,884	04/19/1977	Cleeland, Jr. <i>et al.</i>	436	547	
	A2	4,391,904	07/05/1983	Litman <i>et al.</i>	435	7.91	
	A3	4,394,448	07/19/1983	Szoka, Jr. <i>et al.</i>	435	458	
	A4	4,744,981	05/17/1988	Pavanasasivam	424	181.1	
	A5	4,897,255	01/30/1990	Fritzberg <i>et al.</i>	530	391.5	
	A6	4,988,496	01/29/1991	Srinivasan <i>et al.</i>	424	1.53	
	A7	5,106,951	04/21/1992	Morgan, Jr. <i>et al.</i>	530	391.9	
	A8	5,186,941	02/16/1993	Callahan <i>et al.</i>	424	450	
	A9	5,474,766	12/12/1995	Schwartz <i>et al.</i>	424	94.64	
	A10	5,962,012	10/05/1999	Lin <i>et al.</i>	424	448	
	A11	5,981,194	11/09/1999	Jeffries <i>et al.</i>	435	7.1	
	A12	6,261,595	07/17/2001	Stanley <i>et al.</i>	424	449	
	A13	6,447,775	09/10/2002	Strickland <i>et al.</i>	424	130.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	No
	B1	WO 01/59459	08/16/2001	PCT				
	B2	WO 02/13843	02/21/2002	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Altschul <i>et al.</i> , <i>J. Mol. Biol.</i> , 215(3) :403-410 (1990)
	C2	Ashcom <i>et al.</i> , <i>J. Cell. Biol.</i> , 110(4) :1041-1048 (1990)
	C3	Bickel <i>et al.</i> , <i>Adv. Drug Deliv. Rev.</i> , 46(1-3) :247-279 (2001)
	C4	Blair <i>et al.</i> , <i>J. Immunol. Methods</i> , 59(2) :129-143 (1983)
	C5	Blättler <i>et al.</i> , <i>Biochem.</i> , 24 :1517-1524 (1985)
	C6	Bu <i>et al.</i> , <i>J. Biol. Chem.</i> , 271(36) :22218-2224 (1996)
	C7	Bu <i>et al.</i> , <i>Trends Cell. Biol.</i> , 8(7) :272-276 (1998)
	C8	Czekay <i>et al.</i> , <i>Mol. Biol. Cell.</i> , 8(3) :517-532 (1997)
	C9	Dehouck <i>et al.</i> , <i>J. Cell. Biol.</i> , 138(4) :877-889 (1997)
	C10	Fahrländer <i>et al.</i> , <i>Bio/Technology</i> , 6 :1165-1168 (1988)
	C11	Feng <i>et al.</i> , <i>J. Mol. Evol.</i> , 25 :351-360 (1987)
	C12	Fillebeen <i>et al.</i> , <i>J. Biol. Chem.</i> , 274(11) :7011-7017 (1999)
	C13	FitzGerald <i>et al.</i> , <i>J. Cell Biol.</i> , 129(6) :1533-1541 (1995)
	C14	Genbank Accession No. AAH49517
	C15	Genbank Accession No. AAM90301
	C16	Genbank Accession No. CAA05085
	C17	Genbank Accession No. NP_506187
	C18	Genbank Accession No. NP_649950

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

30610/40037

Serial No.

10/812,849

INFORMATION DISCLOSURE STATEMENT

Applicant

Zankel *et al.*

Filing Date

March 30, 2004

Group

1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C19	Genbank Accession No. P30533
C20	Genbank Accession No. Q99068
C21	Genbank Accession No. X13916
C22	Genbank Accession No. XP_132029
C23	Genbank Accession No. XP_313261
C24	Gutierrez <i>et al.</i> , <i>J. Neuroimmunology</i> , 47(2) :169-176 (1993)
C25	Henikoff <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89 :10915 (1989)
C26	Herz <i>et al.</i> , <i>Atherosclerosis</i> , 118 Suppl :S37-S41 (1995)
C27	Herz <i>et al.</i> , <i>J. Biol. Chem.</i> , 266(32) :21232-21238 (1991)
C28	Herz <i>et al.</i> , <i>J. Clin. Invest.</i> , 108(6) :779-784 (2001)
C29	Higgins <i>et al.</i> , <i>Comput. Appl. Biosci.</i> , 5(2) :151-153 (1989)
C30	Hoogerbrugge <i>et al.</i> , <i>Lancet</i> , 345(8962) :1398-1402 (1995)
C31	Jensen <i>et al.</i> , <i>FEBS Lett.</i> , 255(2) :275-280 (1989)
C32	Karlin <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 90(12) :5873-5877 (1993)
C33	Kilic <i>et al.</i> , <i>Stroke</i> , 34(5) :1304-1310 (2003)
C34	King <i>et al.</i> , <i>Biochem.</i> , 25(19) :5774-5779 (1986)
C35	Kushuhara <i>et al.</i> , <i>Drug Discov. Today</i> , 6(3) :150-156 (2001)
C36	Lin <i>et al.</i> , <i>Science</i> , 260(5111) :1130-1132 (1993)
C37	Medved <i>et al.</i> , <i>J. Biol. Chem.</i> , 274(2) :717-727 (1999)
C38	Meilinger <i>et al.</i> , <i>FEBS Lett.</i> , 360(1) :70-74 (1995)
C39	Melman <i>et al.</i> , <i>J. Biol. Chem.</i> , 276(31) :29338-29346 (2001)
C40	Needleman <i>et al.</i> , <i>J. Mol. Biol.</i> , 48(3) :443-453 (1970)
C41	Nielsen <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 94(14) :7521-7525 (1997)
C42	Orlando <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 91(8) :3161-3165 (1994)
C43	Pardridge, <i>J. Neurovirol.</i> , 5(6) :556-569 (1999)
C44	Pearson <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 85(8) :2444-2448 (1988)
C45	Rall <i>et al.</i> , <i>J. Biol. Chem.</i> , 273(37) :24152-24157 (1998)
C46	Savonen <i>et al.</i> , <i>J. Biol. Chem.</i> , 274(36) :25877-25882 (1999)
C47	Smith <i>et al.</i> , <i>Adv. Appl. Math.</i> , 2 :482-489 (1981)
C48	Srinivasachar <i>et al.</i> , <i>Biochem.</i> , 28(6) :2501-2509 (1989)
C49	SwissProt Primary Accession No. Q07954
C50	Takahashi <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89(19) :9252-9256 (1992)
C51	Thompson <i>et al.</i> , <i>Nucleic Acids Res.</i> , 22(22) :4673-4680 (1994)
C52	Tsuji <i>et al.</i> , <i>Adv. Drug Deliv. Rev.</i> , 36(2-3) :277-290 (1999)
C53	Warshawsky <i>et al.</i> , <i>J. Biol. Chem.</i> , 269(5) :3325-3330 (1994)
C54	Wilchek <i>et al.</i> , <i>Anal. Biochem.</i> , 171 :1-32 (1988)
C55	Williams <i>et al.</i> , <i>J. Biol. Chem.</i> , 267(13) :9035-9040 (1992)
C56	Willnow <i>et al.</i> , <i>J. Biol. Chem.</i> , 267(36) :26172-26180 (1992)
C57	Wisselaar <i>et al.</i> , <i>J. Biol. Chem.</i> , 268(3) :2223-2231 (1993)
C58	Yenofsky <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 87(9) :3435-3439 (1990)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.